|
Real-time
Oslo Bors
09:36:37 2026-10-27 EDT
|
5-day change | 1st Jan Change | ||
| 13.20 NOK | -1.49% |
|
+2.72% | -44.54% |
| 10-20 | Navamedic Extends Nordic Rights for Mysimba Obesity Drug | MT |
| 10-20 | Navamedic ASA Extends Mysimba Distribution Agreement With Azurity Pharmaceuticals | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 34.5M | - | ||||
| 1,140B | |||||
| 641B | |||||
| 507B | |||||
| 383B | |||||
| 347B |
- Stock Market
- Stocks
- NAVA Stock
- Charts Navamedic ASA
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
